Regeneron Pharmaceuticals (REGN) is about to have a chance to prove that its pricey, seldom-used cardiovascular drug can actually improve patients’ lives — an outcome that would also allow it to remove the air quotes from its “blockbuster” product.

Some time this quarter, Regeneron will release clinical trial data showing whether Praluent, an injected therapy that blasts away bad cholesterol, is better than yesteryear drugs at preventing heart attack, stroke, and hospitalization. That will determine whether the company can compete with Amgen (AMGN), its bitter rival in marketplace and courtroom alike.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.